Jump to Main Content
Polymeric antigen BLSOmp31 in aluminium hydroxide induces serum bactericidal and opsonic antibodies against Brucella canis in dogs
- Clausse, Maria, Díaz, Alejandra G., Pardo, Romina P., Zylberman, Vanesa, Goldbaum, Fernando A., Estein, Silvia M.
- Veterinary immunology and immunopathology 2017 v.184 pp. 36-41
- Beagle, Brucella melitensis biovar Canis, agglutination tests, aluminum hydroxide, antibacterial properties, antibodies, antigens, antiserum, bacteria, blood serum, brucellosis, cell-mediated immunity, dogs, gels, humoral immunity, immune response, immunization, immunoglobulin G, mice, neutrophils, phagocytosis, vaccines
- Polymeric antigen BLSOmp31 is an immunogenic vaccine candidate that confers protection against Brucella canis in mice. In this preliminary study, the immunogenicity and safety of BLSOmp31 adsorbed to aluminum hydroxide gel (BLSOmp31-AH) were evaluated in Beagle dogs. In addition, the potential to elicit serum antibodies with complement-dependent bactericidal activity and/or to enhance phagocytosis by neutrophils were analyzed. Dogs were immunized three times with BLSOmp31-AH by subcutaneous route, followed by an annual booster. The vaccine elicited specific antibodies 3 weeks after the first immunization. Annual booster induced comparable antibody response as the primary series. Humoral immune response stimulated by BLSOmp31-AH did not interfere with routine agglutination test for canine brucellosis. Antibodies demonstrated a high complement-dependent bactericidal activity against B. canis. Moreover, opsonization by immune serum not only stimulated binding and uptake of the bacteria by neutrophils but effectively enhanced the destruction of B. canis. Specific IgG was detected in 3/4 immunized dogs in preputial secretions. The antibody profile corresponded to a marked Th2 response, since IgG1 prevailed over IgG2 and cellular immune response was not detected in vitro or in vivo. These results require further evaluation in larger field studies to establish the full prophylactic activity of BLSOmp31 against canine brucellosis.